Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Articles

The directorate highlights its 2016 achievements.

EDQM Releases Annual Report

Two recently-signed agreements will transfer Takeda’s measles and acellular pertussis vaccine technologies to India-based multinational company Biological E. Limited to develop low-cost combination vaccines including diphtheria, tetanus and acellular pertussis (DTaP), and measles-rubella (MR) vaccines.

Biological E Licenses Combination Vaccine Development from Takeda

BIO report measures decade-long investment and acquisition trends for emerging biotech companies.


Report: Biopharma Investments Down in 2016

Drug sales forecasts fall for first time in 10 years, thanks to pressures to reduce drug prices and the advent of biosimilars.


Pricing Pressure Drives Down Drug Sales Forecasts

The agency announced it is taking steps to increase competition within the prescription drug market.


FDA Acts to Improve Market Competition

Takeda inaugurated expanded capacity of solid-dosage drugs at its site in Oranienburg, Germany.

Takeda Finishes Construction of Manufacturing Facility in Germany

The European Medicines Agency approved Prezista (darunavir) made via a continuous manufacturing process at Janssen's facility in Puerto Rico.

EMA Approves Janssen Drug Made Via Continuous Manufacturing

The agency recommended approval of treatments for hepatitis C, cancer, multiple sclerosis, and arthritis.


EMA Recommends Approval for Eight New Drugs, One Biosimilar

A loan from the European Investment Bank will give BiondVax resources for Phase III trials and a manufacturing facility for its universal flu vaccine.


BiondVax Receives European Union Investment in Universal Flu Vaccine Development

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

The need for flexibility and higher quality are driving advances in parenteral manufacturing and fill/finish equipment. 